Adaptimmune Therapeutics PLC
OTC · CIK 0001621227 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$21.0M
Cost Of Revenue
$3.4M
Operating Income
$-76.0M
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $21.0M | - | - |
| Cost Of Revenue | $3.4M | - | - |
| Operating Income | $-76.0M | - | - |
| Net Income | $-77.9M | - | - |
| Eps Basic | -0.05 | - | - |
| Eps Diluted | -0.05 | - | - |
| Cash And Equivalents | $26.1M | - | - |
| Total Assets | $130.6M | - | - |
| Total Liabilities | $201.6M | - | - |
| Shareholders Equity | $-71.0M | - | - |
| Operating Cash Flow | $-101.4M | - | - |
| Capital Expenditures | $1.3M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Adaptimmune Therapeutics PLC | 2025-08-13 | 0001558370-25-011307 |